Abstract

In the first part of this paper I consider whether an academic bioethicist is likely to change the arguments she is prepared to voice if she is in receipt of payment from a corporation. I argue that she is not, so long as a number of conditions are met regarding the size of payment, the values of the academic bioethics community, the degree to which she participates in that community, and the transparency of corporate involvements. In the second half I consider a different concern that one might have with corporate payments that relate to the dubious nature of the functions bioethicists might play within those corporations. I argue that three roles—those of marketer, expert and lobbyist—are best avoided, but that a fourth—the dialectical role—does provide a legitimate niche within which a bioethicist may offer consultation.